New data from Novo Nordisk’s Phase IIIa ONWARDS 2 trial studying insulin icodec shows it is effective as a once-weekly treatment for Type 2 diabetes. Insulin icodec differs from other basal insulin products currently on the market, as they require once-daily injections. The trial reached its primary endpoint, with 37% of adults with type 2 diabetes who received the drug achieving an HbA1C less than 7% without having any indications of low blood sugar (hypoglycemia). This compared to 27% of patients receiving insulin degludec at 26 weeks.
On a Diabetes Treatment Satisfaction Questionnaire (DTSQ), participants indicated significantly greater satisfaction with the once-weekly insulin icodec compared to insulin degludec. In June, Novo Nordisk reported results from two Phase IIIa comparative trials showing insulin icodec was non-inferior to Sanofi’s insulin glargine, Lantus. The results of ONWARDS 1 demonstrated superiority over insulin glargine. ONWARDS 6 evaluated insulin icodec to Novo’s own Tresiba (insulin dugludec). This trial also hit its primary endpoint, demonstrating superiority over Tresiba.
Read more here